Role of 5-HT2A and 5-HT2C/B receptors in the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on striatal single-unit activity and locomotion in freely moving rats

Psychopharmacology

Volumn 181, Issue 4, 2005, Pages 676-687

  Ball, Kevin T ^a   Rebec, George V ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

5 HT2A; 5 HT2C B; Drug abuse; Freely moving rat; MDMA; SB 206553; Serotonin; Single unit electrophysiology; SR 46349B; Striatum

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; EPLIVANSERIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; DOPAMINE; FLUOROBENZENE; INDOLE DERIVATIVE; PHENOL DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 2B RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ELECTROENCEPHALOGRAM; FEEDBACK SYSTEM; LOCOMOTION; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE UNIT ACTIVITY; ANIMAL; DRUG ABUSE; ELECTROENCEPHALOGRAPHY; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; CORPUS STRIATUM; DOPAMINE; ELECTROENCEPHALOGRAPHY; FLUOROBENZENES; INDOLES; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONS; PHENOLS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 25844470246     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0038-z     Document Type: Article

References (87)

1. Aulakh CS, Hill JL, Wozniak KM, Murphy DL (1988) Fenfluramine-induced suppression of food intake and locomotor activity is differentially altered by the selective type A monoamine oxidase inhibitor clorgyline. Psychopharmacology 95:313-317
2. Ball KT, Budreau D, Rebec GV (2003) Acute effects of 3,4- methylenedioxymethamphetamine on striatal single-unit activity and behavior in freely moving rats: differential involvement of dopamine D1 and D2 receptors. Brain Res 994:203-215
3. 2 receptors. Neuropsychopharmacology 26:40-52
4. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159-163
5. Beardsley PM, Balster RL, Harris LS (1986) Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend 18:149-157
6. 2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA. Psychopharmacology 173:326-336
7. Callaway CW, Wing L, Geyer MA (1990) Serotonin release contributes to the stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 254:456-464
8. Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA (2002) The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97:1531-1536
9. Cornish JL, Shahnawaz Z, Thompson MR, Wong S, Morley KC, Hunt GE, McGregor IS (2003) Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 482:339-341
10. Cottler LB, Womack SB, Compton WM, Ben-Abdallah A (2001) Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol Clin Exp 16:599-606
11. Crespi D, Mennini T, Gobbi M (1997) Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylenedioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 121:1735-1743
12. Daniela E, Brennan K, Gittings D, Hely L, Schenk S (2004) Effects of SCH 23390 on (±)3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol Biochem Behav 77:745-750
13. Deadwyler SA (1986) Electrophysiological investigations of drug influences in the behaving animal. In: Geller HM (ed) Modern methods in pharmacology, vol 3, electrophysiological techniques in pharmacology. Alan R. Liss, New York, pp 1-15
14. Dowling GP, McDonough ET, Bost RO ( 1987) "Eve" and "ecstasy": a report of five deaths associated with the use of MDEA and MDMA. JAMA 257:1615-1617
15. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G (2002) 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology 161:356-364
16. Fischman MW, Johanson CE (1996) Cocaine. In: Schuster CR, Kuhar MJ (eds) Pharmacological aspects of drug dependence: towards an integrated neurobehavioral approach. Springer, Berlin Heidelberg New York, pp 159-195
17. Fletcher PJ, Robinson SR, Slippoy DL (2001) Pre-exposure to (±)3,4-methylenedioxymethamphetamine (MDMA) facilitates acquisition of intravenous cocaine self-administration in rats. Neuropsychopharmacology 25:195-203
18. Fletcher PJ, Korth KM, Robinson SR, Baker GB (2002) Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology 162:282-291
19. Fone KCF, Beckett SRG, Topham IA, Swettenham J, Ball M, Maddocks L (2002) Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology 159:437-444
20. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205-221
21. Gold LH, Koob GF, Geyer MA (1988) Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4- methylenedioxyamphetamine in rats. J Pharmacol Exp Ther 247:547-555
22. Gold LH, Hubner CB, Koob GF (1989) A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology 99:40-47
23. Gough B, Ali SF, Slikker W Jr, Holson RR (1991) Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 39:619-623
24. Gudelsky GA, Nash JF (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66:243-249
25. Haracz JL, Tschanz JT, Greenberg J, Rebec GV (1989) Amphetamine-induced excitations predominate in single neostriatal neurons showing motor-related activity. Brain Res 489:365-368
26. Haracz JL, Tschanz JT, Wang Z, White IM, Rebec GV (1993) Striatal single-unit responses to amphetamine and neuroleptics in freely moving rats. Neurosci Biobehav Rev 17:1-12
27. Haracz JL, Tschanz JT, Wang Z, Griffith KE, Rebec GV (1998) Amphetamine effects on striatal neurons: implications for models of dopamine function. Neurosci Biobehav Rev 22:613-622
28. Harris KD, Henze DA, Csicsvari J, Hirase H, Buzsaki G (2000) Accuracy of tetrode spike separation as determined by simultaneous intracellular and extracellular measurements. J Neurophysiol 84:401-414
29. Heimer L, Zahm DS, Churchill L, Kalivas PW, Wohltmann C (1991) Specificity in the projection patterns of the accumbal core and shell in the rat. Neuroscience 41:89-125
30. Hekmatpanah CR, Peroutka SJ (1990) 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4- methylenedioxymethamphetamine and related agents. Eur J Pharmacol 177:95-98
31. Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340:384-387
32. Kalivas PW, Duffy P, White SR (1998) MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 18:469-479
33. Kankaanpaa A, Meririnne E, Lillsunde P, Seppala T (1998) The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol Biochem Behav 59:1003-1009
34. 2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsycopharmacology 15:116-124
35. 2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117:427-434
36. Kiyatkin EA, Rebec GV (1997) Iontophoresis of amphetamine in the neostriatum and nucleus accumbens of awake, unrestrained rats. Brain Res 771:14-24
37. Koch S, Galloway MP (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104:135-146
38. Kosobud AEK, Harris GC, Chapin JK (1994) Behavioral associations of neuronal activity in the ventral tegmental area of the rat. J Neurosci 14:7117-7129
39. Lamb RJ, Griffiths RR (1987) Self-injection of D,L-3-4- methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology 91:268-272
40. 2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem 74:693-701
41. Marona-Lewicka D, Rhee G-S, Sprague JE, Nichols DE (1996) Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol Biochem Behav 53:99-105
42. Matthews RT, Champney TH, Frye GD (1989) Effects of (±)3,4- methylenedioxymetamphetamine (MDMA) on brain dopaminergic activity in rats. Pharmacol Biochem Behav 33:741-747
43. 1B/1D receptors. J Pharmacol Exp Ther 290:965-973
44. 3H-5-hydroxytryptamine. Pharmacol Biochem Behav 38:505-512
45. McNamara MG, Kelly JP, Leonard BE (1995) Some behavioural and neurochemical aspects of subacute (±)3,4-methylenedioxymethamphetamine administration in rats. Pharmacol Biochem Behav 52:479-484
46. Meyer A, Mayerhofer A, Kovar K-A, Schmidt WJ (2002) Rewarding effects of the optical isomers of 3,4-methylenedioxymethylamphetamine ('ecstasy') and 3,4-methylenedioxyethylamphetamine ('eve') measured by conditioned place preference in rats. Neurosci Lett 330:280-284
47. 2A antagonist. Behav Brain Res 73:163-167
48. Nash JF, Brodkin J (1991) Microdialysis studies on 3,4- methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther 259:820-825
49. National Research Council of the National Academies (2003) Guidelines for the care and use of mammals in neuroscience and behavioral research. National Academy Press, Washington, DC
50. 2 receptors. J Neurosci Res 55:600-607
51. Obradovic T, Imel KM, White SR (1996) Methylenedioxymethamphetamine- induced inhibition of neuronal firing in the nucleus accumbens is mediated by both serotonin and dopamine. Neuroscience 74:469-481
52. Obradovic T, Imel KM, White SR (1998) Repeated exposure to methylenedioxymethamphetamine (MDMA) alters nucleus accumbens neuronal responses to dopamine and serotonin. Brain Res 785:1-9
53. O'Shea E, Granados R, Esteban B, Colado MI, Green AR (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37:919-926
54. Parrott AC (2002) Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837-844
55. 1B/1A receptor agonist, potentiates cocaine-induced increases in nucleus accumbens dopamine. Synapse 32:132-135
56. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic, New York
57. 2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26:311-324
58. Ratzenboeck E, Saria A, Kriechbaum N, Zernig G (2001) Reinforcing effects of MDMA ('ecstasy') in drug-naïve and cocaine-trained rats. Pharmacology 62:138-144
59. Rebec GV (1998) Behavioral pharmacology of amphetamines. In: Tarter RE, Ott PJ, Ammerman RT (eds) Handbook of substance abuse: neurobehavioral pharmacology. Plenum Press, New York, pp 515-527
60. Rebec GV, Haracz JL, Tschanz JT, Wang Z, White I (1991) Responses of motor- and nonmotor-related neostriatal neurons to amphetamine and neuroleptic drugs. In: Bernardi G, Carpenter MB, Di Chiara G, Morelli M, Stanzione P (eds) Basal ganglia III, advances in behavioral biology, vol 39. Plenum Press, New York, pp 463-470
61. Reid LD, Hubbell CL, Tsai J, Fishkin MD, Amendola CA (1996) Naltrindole, a delta-opioid antagonist, blocks MDMA's ability to enhance pressing for rewarding brain stimulation. Pharmacol Biochem Behav 53:477-480
62. Ricaurte GA, Yuan J, McCann UD (2000) (±)3,4- Methylenedioxymethamphetamine ('ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42:5-10
63. Rieke F, Warland D, de Ruyter van Steveninck R, Bialek W (1997) Spikes (Exploring the neural code). MIT Press, Cambridge, MA
64. 2 dopamine receptors in amphetamine-induced changes in striatal unit activity in behaving rats. Brain Res 619:347-351
65. Rudnick G, Wall SC (1992) The molecular mechanism of "ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89:1817-1821
66. Schenk S, Gittings D, Johnstone M, Daniela E (2003) Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology 169:21-27
67. 2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4- methylenedioxymethamphetamine. Eur J Pharmacol 223:65-74
68. Schmitzer-Torbert N, Jackson J, Henze D, Harris K, Redish AD (2005) Quantitative measures of cluster quality for use in extracellular recordings. Neuroscience 131:1-11
69. 1A agonists. J Pharmacol Exp Ther 273:101-112
70. Segal DS, Kuczenski R (1994) Behavioral pharmacology of amphetamine. In: Cho A, Segal DS (eds) Amphetamine and its analogs. Academic, San Diego, CA, pp 115-150
71. Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33:639-677
72. Slikker W Jr, Holson RR, Ali SF, Kolta MG, Paule MG, Scallet AC, McMillan DE, Bailey JR, Hong JS, Scalzo FM (1989) Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 10:529-542
73. Spanos LJ, Yamamoto BK (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(±)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav 32:835-840
74. Tschanz JT, Haracz JL, Griffith KE, Rebec GV (1991) Bilateral cortical ablations attenuate amphetamine-induced excitations of neostriatal motor-related neurons in freely moving rats. Neurosci Lett 134:127-130
75. Tschanz JT, Griffith KE, Haracz JL, Rebec GV (1994) Cortical lesions attenuate the opposing effects of amphetamine and haloperidol on neostriatal neurons in freely moving rats. Eur J Pharmacol 257:161-167
76. Wakonigg G, Sturm K, Saria A, Zernig G (2003) Methylenedioxymethamphetamine (MDMA, 'ecstasy') serves as a robust positive reinforcer in a rat runway procedure. Pharmacology 69:180-182
77. Wang Z, Rebec GV (1993) Neuronal and behavioral correlates of intrastriatal infusions of amphetamine in freely moving rats. Brain Res 627:79-88
78. Warenycia MW, McKenzie GM (1984) Immobilization of rats modifies the response of striatal neurons to dexamphetamine. Pharmacol Biochem Behav 21:53-59
79. West MO (1998) Anesthetics eliminate somatosensory-evoked discharges of neurons in the somatotopically organized sensorimotor striatum of the rat. J Neurosci 18:9055-9068
80. West MO, Peoples LL, Michael AJ, Chapin JK, Woodward DJ (1997) Low-dose amphetamine elevates movement-related firing of rat striatal neurons. Brain Res 745:331-335
81. White SR, Duffy P, Kalivas PW (1994) Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo. Neuroscience 62:41-50
82. White SR, Harris GC, Imel KM, Wheaton MJ (1995) Inhibitory effects of dopamine and methylenedioxymethamphetamine (MDMA) on glutamate-evoked firing of nucleus accumbens and caudate/putamen cells are enhanced following cocaine self-administration. Brain Res 681:167-176
83. White SR, Obradovic T, Imel KM, Wheaton MJ (1996) The effects of methylenedioxymethamphetamine (MDMA, 'ecstasy') on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 49:455-479
84. Yamamoto BK, Spanos LJ (1988) The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 148:195-203
85. Yamamoto BK, Nash JF, Gudelsky GA (1995) Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and γ-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273: 1063-1070
86. Zahm DS, Heimer L (1993) Specificity in the efferent projections of the nucleus accumbens in the rat: comparison of the rostral pole projection patterns with those of the core and shell. J Comp Neurol 327:220-232
87. Ziance RJ, Sipes IG, Kinnard WJ, Buckley JP (1972) Central nervous system effects of fenfluramine hydrochloride. J Pharmacol Exp Ther 180:110-117